Summary

for people ages 12-75 (full criteria)
at UC Davis
study started
estimated completion

Description

Summary

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe Atopic Dermatitis (AD) who are candidates for systemic therapy.

Official Title

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis

Keywords

Atopic Dermatitis Upadacitinib Dermatitis Dermatitis, Atopic Eczema

Eligibility

You can join if…

Open to people ages 12-75

  • Active moderate to severe atopic dermatitis defined by Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Body surface area (BSA), and pruritus
  • Candidate for systemic therapy or have recently required systemic therapy for atopic dermatitis.

You CAN'T join if...

  • Prior exposure to any Janus kinase (JAK) inhibitor
  • Unable or unwilling to discontinue current atopic dermatitis (AD) treatments prior to the study
  • Requirement of prohibited medications during the study
  • Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
  • Female subject who is pregnant, breastfeeding, or considering pregnancy during the study

Locations

  • UC Davis /ID# 203622 accepting new patients
    Sacramento California 95817 United States
  • California Allergy and Asthma Medical Group /ID# 200727 accepting new patients
    Los Angeles California 90025-7014 United States
  • Dermatology Clinical Trials /ID# 205876 accepting new patients
    Newport Beach California 92660-7853 United States
  • Synergy Dermatology /ID# 200842 accepting new patients
    San Francisco California 94132-1909 United States
  • Tien Q Nguyen MD, Inc /ID# 201910 accepting new patients
    Fountain Valley California 92708-3701 United States
  • Allergy & Asthma Associates of Southern California /ID# 200733 accepting new patients
    Mission Viejo California 92691-6410 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT03569293
Phase
Phase 3
Study Type
Interventional
Last Updated